Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rosalind Rei

Reporter

London, UK

Rosalind Rei has a background in science communication and business journalism. Before joining Generics Bulletin in 2022, she worked as a freelance writer and researcher covering sustainability, biotech, biomaterials, climate science, and carbon finance. She has also written and produced episodes on the history of science for the Harvard-based podcast Ministry of Ideas.

She holds a master’s in the history and philosophy of science and takes keen interests in political economy, ecology, and environment.

Latest From Rosalind Rei

Neuraxpharm’s New Belgian Division Advances European Expansion Strategy

Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established. 

Belgium Business Strategies

Pfizer Adds Hundreds Of Drugs To Global Health Equity Initiative

Pfizer has added hundreds of off-patent products to the portfolio that it is offering on a not-for-profit basis to 45 lower-income countries under its global health equity initiative.

International Business Strategies

IGBA Struggles To Find Data On Global Drug Shortages For WHO

An IGBA research report suggests international health bodies lack an accurate picture of global essential medicines shortages due to issues with monitoring and recording.

International Supply Chain

Sun Forwards Specialty Strategy With $576m Concert Acquisition

Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.

Deals M & A

Jonathan Kimball Named IGBA Chair For 2023

The IGBA chair passes to Jonathan Kimball. He will head the global off-patent industry organization as it steps up its activities in global policy.

International Generic Drugs

Alvotech’s Simponi Rival Begins Pharmacokinetic Study

Alvotech’s Simponi rival enters Phase I trials after a dynamic year for the company’s development and commercialization program. Meanwhile, the biosimilars developer has also expanded its Japanese collaboration with Fuji Pharma.

United States Clinical Trials
See All
UsernamePublicRestriction

Register